ODD,
Bifidobacterium longum,
Health,
Disease,
Incidence,
Partnership,
Risk,
Necrotizing enterocolitis,
Health maintenance organization,
Biomarker,
Disorder,
Milk,
Mortality,
Bacteria,
Infant,
Death,
United,
NEC,
Mucus,
Marketing,
FDA,
Food,
Pharmaceutical industry DAVIS, Calif., April 2, 2024 /PRNewswire/ -- Infinant Health, a privately-held company focused on changing the trajectory of human health, one baby at a time, announced it has filed an application with the U.S. Food and Drug Administration (FDA) to receive Orphan Drug Designation (ODD) for its drug candidate INF108 for the prevention of necrotizing enterocolitis in pre-term infants.
Key Points:
- DAVIS, Calif., April 2, 2024 /PRNewswire/ -- Infinant Health, a privately-held company focused on changing the trajectory of human health, one baby at a time, announced it has filed an application with the U.S. Food and Drug Administration (FDA) to receive Orphan Drug Designation (ODD) for its drug candidate INF108 for the prevention of necrotizing enterocolitis in pre-term infants.
- The FDA grants Orphan Drug Designation status to products that treat rare diseases, providing incentives to sponsors developing drugs or biologics.
- Orphan Drug Designation would qualify INF108 for certain benefits and incentives, including seven years of marketing exclusivity if regulatory approval is ultimately received for the designated indication, potential tax credits for certain activities, eligibility for orphan drug grants, and the waiver of certain administrative fees.
- The receipt of Orphan Drug Designation status does not change the regulatory requirements or process for obtaining marketing approval.
Retrieved on:
Wednesday, August 16, 2023
Food,
Parent,
The Non-GMO Project,
Oxygen,
GMO,
Health,
Light,
Research,
Certification,
PVP,
Infant,
Probiotic,
Breast milk,
Dietary supplement DAVIS, Calif., Aug. 16, 2023 /PRNewswire/ -- Infinant Health, Inc, a company focused on improving infant health through research of the gut microbiome, announced it has received certifications from Nutrasource's IPRO™ (International Probiotic Standards) for its Evivo infant probiotic product portfolio and the Non-GMO Project for its Evivo with liquid products. Evivo has been used for five years with over 4 million feedings to date in over 60,000 babies – promoting good gut bacteria to protect babies from within.
Key Points:
- IPRO and Non-GMO certifications for Evivo infant probiotic showcase the company's commitment to infant health.
- IPRO™ (International Probiotic Standards) is a certification by Nutrasource that is specifically designed for probiotic ingredients and finished products.
- IPRO helps companies be more transparent in how their probiotics are manufactured, handled, tested, stored, shipped, and labeled.
- "These certifications for Evivo are a part of our commitment to deliver the highest quality probiotics for our most precious family members.
Allergy,
Food,
Infinity Festival Hollywood,
Librarian,
Parent,
Mother,
Health,
Inflammation,
Element,
Consultant,
Nicu's Spoon Theater Company,
MCA,
Hospital,
Lactation,
Ethics,
Infant,
Web Cartoonists' Choice Awards,
FDA,
Parents' Choice Award,
Pediatrics,
Breast milk,
Nursing,
Dietary supplement DAVIS, Calif., May 16, 2023 /PRNewswire/ -- Infinant Health, Inc, a company focused on improving infant health through the gut microbiome, announced its flagship product, Evivo, is a recipient of this year's Mom's Choice Award. This designation reflects Evivo's place as a best-in-class product widely used by parents and highly recommended by pediatricians, lactation consultants and other medical professionals. Evivo is also used in hospitals and NICUs throughout the U.S.
Key Points:
- DAVIS, Calif., May 16, 2023 /PRNewswire/ -- Infinant Health, Inc , a company focused on improving infant health through the gut microbiome, announced its flagship product, Evivo, is a recipient of this year's Mom's Choice Award.
- The Mom's Choice Awards evaluates products and services created for children, families and educators.
- "We are happy to award deserving products like Evivo," said Dawn Matheson, CEO, Mom's Choice Awards.
- Infinant Health's mission is to change the trajectory of human health, one baby at a time, through a deep understanding of infant nutrition and the gut microbiome.
Retrieved on:
Thursday, January 19, 2023
Cargill,
Hospital,
Parent,
Epicor,
Health,
Knowledge,
Immune system,
Growth,
Science,
Infant,
Pharmaceutical industry,
Management DAVIS, Calif., Jan. 19, 2023 /PRNewswire/ -- Today, Infinant Health, Inc, a company focused on improving infant health through the gut microbiome, announced that Mike Johnson has been named Chief Executive Officer to lead the company into its next phase of growth and expansion. The company will continue to leverage its key discoveries in the microbiome of the gut to develop innovative solutions that positively influence infant health.
Key Points:
- DAVIS, Calif., Jan. 19, 2023 /PRNewswire/ -- Today, Infinant Health, Inc, a company focused on improving infant health through the gut microbiome, announced that Mike Johnson has been named Chief Executive Officer to lead the company into its next phase of growth and expansion.
- "We are beyond excited to announce Mike Johnson as Infinant Health's Chief Executive Officer," said Brent Drever, Chairman of the Board of Directors for Infinant Health.
- Johnson brings with him a wealth of knowledge and experience in health and technology to Infinant Health.
- "Joining such an innovative, mission-oriented biotechnology company as Chief Executive Officer is beyond exciting, and I cannot wait to work alongside Infinant Health's top-notch team to carry out our strategic vision for the future," said Chief Executive Officer Mike Johnson.
Retrieved on:
Tuesday, November 15, 2022
Metabolism,
Health,
YEC,
Infant,
Immunity,
Biotechnology,
Q&A,
Safety,
Partnership,
Industry,
Forbes,
Time,
Criterion,
Multimedia,
CEO,
Cognition,
Council,
Infinity Business School,
Pharmaceutical industry,
Public relations NORWALK, Conn., Nov. 15, 2022 /PRNewswire/ -- Kaile Zagger, CEO of Infinant Health, Inc, a privately held biotechnology company committed to changing the trajectory of human health, one baby at a time, has been accepted into the Forbes Business Council, the foremost growth and networking organization for successful business owners and leaders worldwide.
Key Points:
- NORWALK, Conn., Nov. 15, 2022 /PRNewswire/ -- Kaile Zagger, CEO of Infinant Health, Inc, a privately held biotechnology company committed to changing the trajectory of human health, one baby at a time, has been accepted into the Forbes Business Council, the foremost growth and networking organization for successful business owners and leaders worldwide.
- "We are honored to welcome Kaile into the community," said Scott Gerber, founder of Forbes Councils, the collective that includes Forbes Business Council.
- As an accepted member of the Council, Kaile has access to a variety of exclusive opportunities designed to help her reach peak professional influence.
- Forbes Councils is a collective of invitation-only communities created in partnership with Forbes and the expert community builders who founded Young Entrepreneur Council (YEC).
